Intense Pulsed Light plus Perfluorohexyloctane for Moderate-to-Severe MGD-Related Dry Eye
DOI:
Author:
Corresponding Author:

Affiliation:

1.Ophthalmology Department,Putuo District Central Hospital,Shanghai;2.Baoying Guangming Eye Hospital,Yangzhou,Jiangsu Province

Clc Number:

Fund Project:

  • Article
  • |
  • Figures
  • |
  • Metrics
  • |
  • Reference
  • |
  • Related
  • |
  • Cited by
  • |
  • Materials
  • |
  • Comments
    Abstract:

    AIM: To evaluate the clinical efficacy of intense pulsed light (IPL) combined with perfluorohexyloctane eye drops in treating moderate to severe dry eye associated with meibomian gland dysfunction (MGD). METHODS: This is a prospective randomized controlled trial. A total of 84 patients (84 eyes) with MGD-related dry eye were ultimately included in this study. The patients were assigned to three groups: Group A (27 eyes; mean age 52.3 ± 8.1 years; 13 males and 14 females), Group B (28 eyes; mean age 53.1 ± 7.6 years; 14 males and 14 females), and Group C (29 eyes; mean age 51.8 ± 8.4 years; 15 males and 14 females). Ocular Surface Disease Index (OSDI), noninvasive tear film breakup time (NITBUT), corneal fluorescein staining (tCFS), Lipid Layer Thickness (LLT), and adverse events were assessed at baseline, 4 weeks, 8 weeks, and 12 weeks. RESULTS: All three groups showed significant decreases in OSDI, tCFS, , and a significant increase in NITBUT at all post-treatment time points (P<0.05). At corresponding time points, Group C demonstrated superior outcomes compared with Groups A and B, as evidenced at 8 weeks: OSDI was 18.4 ± 4.1 in Group C vs. 26.7 ± 5.3 in Group A and 22.1 ± 4.8 in Group B; NITBUT was 7.9 ± 1.6 s vs. 5.8 ± 1.2 s and 6.7 ± 1.4 s; tCFS was 1.9 ± 0.8 vs. 3.4 ± 1.1 and 2.6 ± 0.9 (all P < 0.05). LLT also improved most notably in Group C, surpassing Groups A and B. CONCLUSIONS: IPL combined with perfluorohexyloctane eye drops was superior to either monotherapy in improving tear film stability and ocular surface staining in patients with moderate to severe MGD-associated dry eye, with longer-lasting effects after treatment cessation and a favorable safety profile.

    Reference
    Related
    Cited by
Get Citation
Article Metrics
  • Abstract:
  • PDF:
Publication History
  • Received:July 30,2026
  • Revised:November 17,2026
  • Adopted:September 29,2026
  • Online: November 17,2026
  • Published: